---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118166"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:12:20.516569+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Onconova Q3 net loss $4.7M; cash $25.2M; narazaciclib dose escalation extended into Q1 2024

## Summary
- Net loss Q3 2023: $4.7M ($0.23/sh) vs $5.4M ($0.26/sh) year ago; cash $25.2M sufficient into Q3 2024.
- Narazaciclib Phase 1/2 dose escalation extended to at least one more cohort; no significant neutropenia or diarrhea.
- Rigosertib registrational trial plan update for RDEB-associated SCC expected in first half of 2024.
- Preclinical data for narazaciclib to be presented at SABCS and ASH in December 2023.
- Appointed Dr. Victor Moyo as CMO and Meena Arora as VP Medical Affairs in Q3 2023.

## SEC filing metadata
- accession: 0001104659-23-118166
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/0001104659-23-118166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/tm2330724d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118166
- JSON: https://secwatch.observer/filing/0001104659-23-118166.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118166.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported third quarter 2023 results: net income Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs, EPS $0.23 per share.
  - Period: third quarter 2023
  - Net income: Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outs
  - EPS: $0.23 per share
  - Result: reported results
  source text: Net loss for the third quarter of 2023 was $4.7 million, or $0.23 per share on 21.0 million weighted average shares outstanding
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/0001104659-23-118166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.